Related Experiment Video
Updated: Aug 9, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Randomized trials in melanoma: an update
1Erasmus Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, EA 3075, Rotterdam, the Netherlands. a.m.m.eggermont@erasmusmc.nl
Abstract:
No effective therapy for metastatic melanoma exists. Polychemotherapy or chemoimmunotherapy have not shown survival benefits. Vaccines have shown little activity in stage IV disease. To advance the identification of effective agents, new drugs can and should be offered as first-line treatment. Efforts must be made to improve understanding of the biology of malignant melanoma. Too many phase III trials have been conducted with a poor understanding of the mechanism of action of the involved drugs.
Insights
No effective therapies exist for metastatic melanoma. New drug development and a deeper understanding of melanoma biology are crucial for advancing treatment options.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Metastatic melanoma currently lacks effective therapeutic strategies.
- Established treatments like polychemotherapy and chemoimmunotherapy have failed to demonstrate survival benefits.
- Vaccine therapies show limited efficacy in stage IV disease.
Purpose of the Study:
- To highlight the urgent need for novel therapeutic agents in metastatic melanoma treatment.
- To emphasize the importance of understanding the underlying biology of malignant melanoma.
- To advocate for the strategic use of new drugs as first-line treatments.
Main Methods:
- Review of current treatment modalities for metastatic melanoma.
- Analysis of the limitations of existing polychemotherapy, chemoimmunotherapy, and vaccine approaches.
- Discussion on the necessity of improved mechanistic understanding for drug development.
Main Results:
- Current therapeutic options for metastatic melanoma are inadequate, offering no survival advantage.
- Phase III trials have often proceeded without a clear understanding of drug mechanisms.
- Significant gaps exist in comprehending the biological drivers of malignant melanoma.
Conclusions:
- New drug candidates should be prioritized as first-line treatments for metastatic melanoma.
- Further research into the biology of malignant melanoma is essential for therapeutic advancement.
- A mechanistic approach is critical for the successful design and execution of clinical trials.
